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 Keratoepithelin (KE) or transforming growth factor-β in-
ducible (TGFβI) protein is an essential constituent of the ex-
tracellular matrix responsible for cell adhesion and cell-ma-
trix interactions. The encoding gene of KE was first discov-
ered from a subtraction library screening in human adenocar-
cinoma cell line A549 treated with transforming growth fac-
tor-β1 (TGFβ-1) [1]. Two other groups later independently
isolated the KE protein from pig cartilages [2] and rabbit cor-
neas [3] as a collagen fiber-associated protein. KE has various
other names such as TGFBI (TGFβ1-induced protein), BIGH3,
βIGH3, βig-h3, beta ig-h3, keratoepithelin, or RGD-CAP (in
chicken and pig) [2,4]. KE is composed of 683 amino acids
and is highly conserved among species (human, mouse,
chicken, and pig). It is widely distributed in human tissues
such as the cornea, skin, lung, bone, bladder, and kidney. Dur-
ing corneal wound healing, upregulation of KE is associated
with an increase of TGFβ-1 [3].
In addition to its role in corneal wound healing [3], KE
also plays an important role in the pathogenesis of several
autosomal dominant corneal dystrophies. In humans, KE is
located at chromosome 5q3l. Several 5q3l-linked corneal dys-
trophies such as lattice type I, Avellino, granular type I, and
Reis-Bückler are correlated with permutations of KE [5-7].
To date, at least 13 different types of KE-related corneal dys-
trophies attributed to at least 30 missense mutations of KE
have been reported. These corneal dystrophies are typically
presented with untoward subepithelial or stromal opacities with
reduced vision and often painful recurrent erosions due to poor
epithelial adhesions. Research evidence indicate that these
corneal opacities are caused by amyloid or non-amyloid pro-
tein aggregates secondary to the accumulation of KE and re-
lated mutant proteins. Perturbation of mutant KE to reduce
the production and/or accumulation of those undesirable mu-
tant proteins may potentially mitigate the aggregation of ab-
normal corneal deposits and associated corneal opacities.
Myocilin (MYOC) is a secretory glycoprotein of 55 kDa
with myosin-like and olfactomedin-like domains, it was first
identified in cultured human trabecular meshwork (TM) cells
treated with dexamethasone [8]. The actual functions of
myocilin remain to be elucidated. Recent myocilin researches
have implied its roles in the regeneration in glial cells and in
the central nerve system [9,10]. Myocilin may also contribute
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to the structural integrity of the myelin sheath of peripheral
nerves [11,12]. In situ hybridization revealed that myocilin is
present in many ocular tissues including sclera, TM, and cor-
nea and in non-ocular tissues such as smooth muscle [13].
Although the actual functions of myocilin in the eye have yet
to be delineated, it is believed that the intracellular accumula-
tion of misfolded mutant myocilins induces apoptosis of TM
cells with subsequent obstruction of TM and increased resis-
tance of aqueous outflow [14-16]. The resultant elevation of
intraocular pressure eventually leads to axon degeneration of
the optic nerve and loss of visual fields. Mutations of MYOC
have been implicated in at least two types of inherited open-
angle glaucoma (OAG) like primary open-angle glaucoma
(POAG) and juvenile open-angle glaucoma (JOAG) [17]. In
humans, MYOC is located in chromosome 1 (1q21-q31) and
was initially named the TIGR (TM-inducible-glucocorticoid-
response protein) gene. Currently, at least 3%-4% of POAG
and JOAG patients have been associated with 43 myocilin
mutations via genetic linkage analysis [18,19].
Human genes can be manipulated by many mechanisms.
RNA interference (RNAi) is a powerful technique for gene
silencing that was first discovered in C. elegans and plants
[20,21]. RNAi can be found in eukaryotes as diverse as yeast
and mammals and likely plays a crucial role in regulating gene
expression in all eukaryotes [22,23]. Currently, there are two
commonly employed methods in applying RNAi for gene sup-
pression: synthetic small interfering RNAs (siRNAs), which
usually are short double-stranded RNAs of 21-23 nucleotide
pairs [22,24-26], and short hairpin siRNAs (shRNAs) gener-
ated by RNA polymerase III promoters such as human H1-
RNA or murine U6 RNA promoters (Figure 1) [24,25]. The
promoter-mediated shRNA technology has recently gained
popularity due to advantages such as low production costs and
prolonged durations of gene suppression. This recent advance
in RNAi technologies would make shRNA-mediated gene
therapies possible if it could be further combined with effica-
cious nucleotide delivery vehicles such as viral vectors or
nanoparticles with high efficiency and low toxicity.
Since mutations of KE and MYOC have been implicated
in autosomal dominant corneal dystrophies and inherited
OAGs, respectively, we surmise that siRNA-mediated sup-
pression of mutant KE and MYOC may potentially mitigate
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Figure 1. Gene silencing by short hairpin RNA.
RNA interference (RNAi)-mediated gene silencing
is a posttranscriptional mechanism targeting a spe-
cific mRNA in which a short double-stranded RNA
of 21-23 nucleotide pairs (known as “small inter-
fering RNA”, siRNA) induces a sequence-specific
knock-down of its complementary gene. To pre-
vent degradation of RNA fragments and to achieve
a stable expression of siRNA in cultured cells, self-
looped short hairpin RNAs (shRNAs) as siRNA
precursors can be designed by linking the sense and
antisense strands of siRNA with an oligonucleotide
linker (spacer) and a poly-T as a terminator. The
sequences can then be subcloned into a plasmid,
containing RNA polymerase III promoters, such as
human H1-RNA promoter to generate shRNAs.
These plasmids can transfect target cells via lipo-
somes or viral vectors. Once inside the cell, the
shRNAs generated by the plasmids are cleaved by
a Dicer (an RNase) to form siRNAs. The double
stranded siRNA is unwound to form a single-
stranded ribonucleoprotein complex known as
RNA-induced silencing complex (RISC), which
mediates a sequence-specific degradation of the
mRNAs involved in coding a target protein. After
pairing with a siRNA strand, the target mRNA is
cleaved and further degraded, leading to an inter-
ruption in synthesis of the disease-causing protein
such as myocilin or keratoepithelin (KE). The RISC
complex is naturally stable thus enabling siRNAs
to interact consecutively with multiple mRNAs with
a potent suppression of protein synthesis. With sup-
pression of mutant KE and myocilin, the
amyloidogenic response from aggregations of ab-
normal KE and the cytotoxic response of trabecu-
lar meshwork caused by misfolded myocilin can
be mitigated, respectively.
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the protein aggregations of abnormal KE in cornea or of ab-
normal myocilin in TM and alleviate the untoward corneal
opacities or glaucoma, respectively. The anterior segment of
the eye is readily accessible for topical delivery of therapeu-
tics to the target tissues such as cornea or trabecular mesh-
work. To investigate the feasibility of shRNA-mediated gene
suppression as a new potential therapeutic strategy for inher-
ited ocular conditions, we produced several shRNAs from the
RNA polymerase III promoter-containing plasmids to evalu-
ate their efficacy in suppressing the expression of KE and
MYOC in vitro.
METHODS
Plasmid construction to generate fusion proteins:  Amplifica-
tion of KE cDNA and construction of expression plasmids were
performed as in our previous report [27]. For experiments re-
garding shRNAs targeting the coding region of KE, cDNA of
human KE was amplified by polymerase chain reaction (PCR)
from an I.M.A.G.E. (Integrated Molecular Analysis of Ge-
nomes and Expression Consortium) clone (clone ID 4837646;
GenBank BE206112) and ligated into a green fluorescent pro-
tein-producing pEGFP-N1 vector to construct KEpEGFP plas-
mids to generate KE-EGFP fusion proteins. The KE gene,
containing the coding region after the signal peptide and addi-
tional downstream 454 bp of the 3'-untranslated region (3'-
UTR), was amplified and subcloned into pEGFP-C3 to evalu-
ate the suppression efficiency of shRNAs targeting the 3'-UTR
region.
The I.M.A.G.E. clone of human MYOC was purchased
from ResGen (clone ID: 5179076; Huntsville, AL). The PCR-
amplified full-length MYOC cDNA was subcloned into
pEGFP-N1 (Clontech, Palo Alto, CA) via BamHI and EcoRI
sites to construct MYOCpEGFP plasmids to produce the
myocilin-EGFP fusion proteins in HEK293 cells (primer se-
quences: HMYOC-BamHI.3: 5'-GGC TGG ATC CAT CTT
GGA GAG CTT GAT G-3', and HMYOC-EcoRI.5: 5'-GAA
GAA TTC ATG AGG TTC TTC TGT GCA C-3'). The trun-
cated myocilin mutant, Q368X, was generated by PCR-am-
plification of a cDNA fragment containing amino acid resi-
dues 1-367 and subsequently fused with EGFP. The specific
sequences were further confirmed by automated sequencing
at the Microchemical Facilities at the University of Minne-
sota.
Plasmid construction to generate short hairpin RNA:
Oligonucleotides, containing the sequence of human H1 RNA
promoter, were synthesized by the Microchemical facilities at
the University of Minnesota. To generate short hairpin RNAs
(shRNAs) to interfere with the expression of fusion proteins,
pH1 plasmids were first produced by subcloning the synthe-
sized human H1-RNA promoter into the pBluescript KS(+) II
(Stratagene, La Jolla, CA) via BamHI and EcoRI sites. The
pH1 plasmids were further digested by BglII and HindIII and
then gel purified. For comparison, we also obtained a mU6P
plasmid from Dr. David Turner at the University of Michigan,
Ann Arbor, MI to generate shRNAs [25]. The mU6P plasmid
contains the murine U6 RNA promoter and has been used in
murine tissues and several other cell lines to generate shRNAs.
We found that both pH1 and mU6P plasmids successfully gen-
erated shRNAs capable of suppressing target genes (data not
shown).
The candidate siRNA sequences specific for human KE
and MYOC were selected and designed by using online tools
from various vendors (such as programs from Ambion or
Oligoengines; see Table 1 for siRNA sequences). The selected
candidate siRNA sequences were also checked to avoid any
possible match with other genes or polymorphism of the tar-
get gene by Blast search. To ensure stable expression of
shRNAs in HEK293 cells, TTCAAGAGA was used as a de-
fault spacer (hairpin loop) sequence for pH1-RNA to generate
shRNAs. The sense and antisense strands of each shRNA con-
taining the selected siRNA sequence, hairpin loop, and
pentathymidine terminator were synthesized and cloned into
the prepared vector arm of pH1 plasmids (named as “KEpH1-
shRNA” or “MYOCpH1-shRNA,”, respectively). For specific
suppression of MYOC, we constructed pH1 plasmids to pro-
duce MYOC-specific shRNAs that were complementary to the
mutated amino acid sequences associated with primary or ju-
venile OAGs (R76K, E352K, K423E, and N480K) as previ-
ously reported by other authors [16,17,28]. A control plasmid
generating shRNA with no sequence similarity to any known
mammalian genes (sequence of the sense strand: 5'-CAG TCG
CGT TTG CGA CTG G-3') was also constructed to serve as
our negative control. The sequences of all our clones were
further confirmed by a standard automated sequencing method
at the Microchemical Facilities at the University of Minne-
sota. For comparison, we also used a commercial plasmid,
pSuper (Oligoengine, Seattle, WA) to generate similar MYOC-
specific shRNAs. The results were comparable between the
pH1 and pSuper (data not shown).
Suppression of KE or MYOC by short hairpin RNA:  The
siRNA-mediated gene suppression experiments were con-
ducted in transformed HEK293 or TM5 cells. HEK293 cells
were purchased from American Tissue Culture Collection
(ATCC, Manassas, VA) and maintained in DMEM/F12 cul-
ture medium (Invitrogen, Carlsbad, CA) with the addition of
10% fetal bovine serum (FBS, HyClone Laboratories, Logan,
UT) and antibiotics at 5% CO2/humid atmosphere. TM5 cells
(obtained from Dr. A. F. Clark of Alcon Research Ltd., Fort
Worth, TX) were maintained in DMEM medium, 10% FBS
without sodium pyruvate as reported previously [29-31]. The
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TABLE 1. PLASMID SEQUENCES FOR SMALL INTERFERING RNAS
    Name          Sequence (sense strand)
-------------   ---------------------------   --------
1. control      5'-AACAGTCGCGTTTGCGACTGG-3'
2. siKE-1528    5'-AAGGGAGACAATCGCTTTAGC-3'   1,528 bp
3. siKE-3’UTR   5'-AACTTGCCCGTCGGTCGCTAG-3'   3'-UTR
4. siMYOC-A     5'-AACTTACAGAGAGACAGCAGC-3'   R76
5. siMYOC-B     5'-AATACCGAGACAGTGAAGGCT-3'   E352
6. siMYOC-C     5'-AACATCCGTAAGCAGTCAGTC-3'   K423
7. siMYOC-D     5'-AACCCCCTGGAGAAGAAGCTC-3'   N480
The oligonucleotide sequences of the sense strands inserted into pH1-
shRNA to generate KE- or MYOC-specific shRNAs for this study. A
Blast search of the control sequence did not find a similarity to any
mammalian genes or to EGFP cDNA.
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media were replenished every other day, and cells were split
twice weekly.
KE-EGFP or MYOC-EGFP plasmids were cotransfected
with the control plasmid or previously selected shRNA-gen-
erating plasmids into HEK293 cells. HEK293 cells were
seeded into 60 mm culture dishes and were grown to a
confluency between 70% and 90%. Transfections of HEK293
cells were performed with lipofectamine (Invitrogen) accord-
ing to the manufacturer’s instructions. For each 60 mm dish,
0.05 µg KEpEGFP was cotransfected with 0.1 µg pCMV-βgal
(Invitrogen) and 1.0 µg of each specific KEpH1-shRNA in
0.5 ml of Opti-MEM. After 4 h of incubation at 37 °C, 1.5 ml
of serum-containing growth medium was added to each plate.
The medium was completely replaced with fresh, serum-con-
taining growth medium at 24 h after transfection. HEK293
cells were harvested at 24 h or 48 h after transfection. The
fluorescent signals of EGFP fusion proteins generated by KE-
EGFP or MYOC-EGFP plasmids in cultured HEK293 cells
were evaluated with an Axiovert 200 fluorescence microscope
(Zeiss, Thornwood, NY) at 48 h after transfection. The reduc-
tion of EGFP-fusion protein fluorescence signal in compari-
son to cotransfection with control plasmid was used as an in-
dicator for the suppression efficiency for each shRNA. To
ensure consistent transfection efficiency in cultured cells
among experiments, a pCMV-βgal (Invitrogn) plasmid that
produces β-galactosidase was included in each transfection
experiment as an internal control. The activity of β-galactosi-
dase was measured with the Luminescent β-gal detection kit
(Clontech) in a Lumat LB9507 luminometer (Berthold Tech-
nologies USA, Oak Ridge, TN) according to the
manufacturer’s instructions. Only transfection experiments
with a variation of less than 10% of β-galactosidase activity
were included for analysis. Five transfections were performed
to evaluate the suppression efficiency of each shRNA.
As lipofectamine caused significant cell death in the TM5
cell line, transfections of this cell line was performed with
Fugene 6 (Roche, Applied Science, Indianapolis, IN). TM5
cells were seeded into six well plates at 50% confluency 24 h
before transfection. Ninety-seven microliters of OptiMem con-
taining 0.5 µg of MYOCpH1-shRNA, 0.025 µg of
MYOCpEGFP, and 0.05 µg of pCMV-βgal were mixed with
3 µl of Fugene 6. After incubation at room temperature for 20
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Figure 2. Suppression of KE-EGFP in HEK293 cells by a short hairpin RNA targeting the coding region of the KE gene.  Cells were trans-
fected with KEpEGFP along with the control plasmid or shRNA-generating plasmid, KE-1528pH1-shRNA. The fluorescence photographs
were taken at the same exposure times (140 msec) 48 h after cotransfections. A: HEK293 cells were cotransfected with KEpEGFP plasmids
and control plasmids as a baseline. B: Fluorescent signals of KE-EGFP in cultured HEK293 cells were significantly reduced by cotransfection
with KE-1528pH1-shRNA. C: Western blot of protein lysates of HEK293 cells from A (lane 1) and from B (lane 2) to demonstrate the
reduction of KE by KE-1528pH1-shRNA is shown. Protein bands (10 µg/lane) were probed with a custom-made anti-KE antibody. Presence
of KE-EGFP fusion proteins in HEK293 cells was noted after cotransfection of KEpEGFP with control plasmid in lane 1 (as indicated by KE).
Significant reduction of KE-EGFP fusion proteins (as indicated by KE) was noted after cotransfection of KEpEGFP with KE-1528pH1-
shRNA in lane 2. D: Northern hybridization of mRNAs from A (left lane) and B (right lane), using IR analysis by Li-Cor, is shown. Equal
amounts of mRNAs were loaded in each lane as judged by the intensities of 28S RNA (as indicated by 28S). Significant reduction of IR signals
of KE-EGFP mRNA (as indicated by KE) was noted after cotransfection of KEpEGFP with KE-1528pH1-shRNA in right lane.
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min, the mixtures were added directly onto cultured cells and
incubated for 24 h. The medium was completely replaced with
fresh medium 24 h after transfection. Cells were harvested
and evaluated similarly to transfected HEK293 cells. The spe-
cific cell confluency and seeding density for HEK293 and TM5
cells (at 70%-90% and 50%, respectively) was determined by
pilot studies to determine the optimal transfection efficiency
(data not shown). Cell viability after transfection by
lipofectamine varied among different cell lines but remained
consistent for the each cell line. For HEK293 cells, as much
as 80% of cells could be transfected by lipofectamine with the
above amount of DNA (1.15 µg per 60 mm plate) with negli-
gible cell death. We noted that the transfection efficiency could
be boosted to 90%-95% by increasing the amounts of DNA
(to more than 2 mg) for transfection. However, transfecting
higher amounts of DNA also led to significant cell death. The
transfection efficiency of TM5 cells by Fugene 6 was only
15% and cell death was less than 10%.
HEK293 or TM5 cells transfected as described above were
harvested at 48 h and subjected to northern hybridization and
western blotting. For northern blot experiments, the RNeasy
mini kit (Qiagen, Valencia, CA) was used for the total RNA
extraction. After the samples were separated on a denaturing
formaldehyde-agarose gel (1.2%) and transferred onto Odys-
sey nylon membrane for Li-Cor Odyssey system (Li-Cor, Lin-
coln, NE), they were hybridized with biotin-labeled KE-spe-
cific oligonucleotide probes (PCR-amplified coding sequences
including exons 12-13). The hybridizations were performed
with the ULTRAhyb-OS Northern kit (Ambion, Austin, TX).
The membranes were further incubated with streptavidin
IRDye 800CW conjugate (Rockland Immunochemicals,
Gilbertsville, PA) to detect biotin-labeled probes and imaged
on the Odyssey IR image system (Li-Cor).
After being rinsed with 1X PBS and trypsinized, a frac-
tion of the cells was removed to determine the activity of β-
galactosidase, and the remaining cells were extracted with ly-
sis buffer (1% SDS/1xPBS) to prepare lysates for western blots.
Protein concentrations of cell lysates were determined using a
BCA Protein Assay Kit (Pierce, Rockford, IL). Equal amounts
of protein (10-20 µg/lane) from each cell lysate were subjected
to electropheresis on 12% SDS-PAGE gels. The gels were blot-
ted onto nitrocellulose membranes at 350 mA for 1 h in the
1X TG buffer (BioRad, Carlsbad, CA)/20% methanol. KE-
EGFP fusion proteins were detected with our custom-made
rabbit anti-KE antibody raised against E.coli-expressed recom-
binant KE [32]. MYOC-EGFP fusion proteins were detected
with a mouse anti-EGFP monoclonal antibody (Clontech) at
1:1,000 dilution followed by a goat anti-mouse secondary an-
tibody conjugated with alkaline phosphatase (Sigma, St. Louis,
MO) at 1:1,000 dilution. The same membranes were also
probed with a mouse anti-β-actin antibody (1:5,000; Sigma)
to determine the amount of β-actin, which would act as an
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Figure 3. Suppression of KE-EGFP in HEK293 cells by a short hair-
pin RNA targeting the 3'-UTR region of KE.  A: HEK293 cells were
cotransfected with KEpEGFP plasmids and control plasmids as a
baseline. B: Fluorescent signals of KE-EGFP in cultured HEK293
cells were significantly reduced by cotransfection with KE-
3’UTRpH1-shRNA. C: Western blot of protein lysates of HEK293
cells from A (lane 1) and from B (lane 2) to demonstrate the reduc-
tion of KE by KE-3’UTRpH1-shRNA is shown. Protein bands (10
µg/lane) were probed with a custom-made anti-KE antibody. Pres-
ence of KE-EGFP fusion proteins in HEK293 cells was noted after
cotransfection of KEpEGFP with control plasmid in lane 1 (as indi-
cated by KE). Significant reduction of KE-EGFP fusion proteins (as
indicated by KE) was noted after cotransfection of KEpEGFP with
KE-3’UTRpH1-shRNA in lane 2.
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internal standard to ensure that equal amounts of protein were
loaded in each lane for electrophoresis. The BCIP/NBT-blue
substrate system (Sigma) was used to visualize the antigen-
antibody complexes, and the colored protein bands were then
scanned and digitized with a flatbed scanner. Quantification
of the digitized bands and β-actin was performed with UN-
SCAN-IT software (Silk Scientific, Orem, UT). The pixel in-
tensities from the bands detected by the anti-EGFP antibody
were normalized to the pixel intensities from the bands de-
tected by anti-β-actin. The ratio of intensities between the con-
trol shRNA and a selected shRNA was used to determine the
suppression efficiency for each shRNA.
Luciferase assay:  To evaluate the protein misfolding re-
sponse and stress of endoplasmic reticulum (ER) caused by
the accumulation of mutant myocilins, we also investigated
the activation of BiP by mutant myocilins in TM5 cells using
luciferase reporter assays (Dual Luciferase Reporter System,
Promega, Madison, WI). A plasmid, BiPpGL3 (a gift from
Dr. C.D. Chen, Boston University, Boston, MA), that contains
rat grp78 (BiP) promoter region -457 to -39 bp and generates
firefly luciferases, was constructed as previously described
[33]. TM5 cells were harvested at 48 h after cotransfection
with MYOCpH1-shRNA (0.1 µg), MYOCpEGFP (0.005 µg),
BiPpGL3 (0.1 µg), and pRL (0.025 µg, generating Renilla
luciferases as internal control). After aspirating the media and
washing cells with 1 ml of 1X PBS, cells were lysed by add-
ing 100 µl of 1X passive lysis buffer (Promega) to each well
of the 24-well plates, and the culture plates were gently shaken
on a rotating platform for 15 min at room temperature. Twenty
microliters of the above lysate was used to measure luciferase
activities with a luminometer as mentioned above. The ex-
pression of firefly luciferases and Renilla luciferases was
measured sequentially for each sample, and the BiP promoter
activity was derived from the ratio of firefly luciferase to
Renilla luciferase.
Statistical analysis:  One-way t-tests were used to deter-
mine the difference in the intensity ratios between myocilin
and β-actin and the luciferase ratios between control and
myocilin-specific shRNAs. At least three sets of transfection
were performed for each experiment with shRNAs unless oth-
erwise stated, and the mean values with standard deviation
were reported. A p<0.05 was used to determine significant
differences between the groups.
RESULTS
Identification and evaluation of keratoepithelin-specific short
hairpin RNAs:  Using several online tools, possible shRNA
candidates for those targeted gene sequences based on algo-
rithms proposed by several groups were searched [22,25]. The
selection of shRNA candidate sequences was based on the GC
content of the gene sequence, the optimal sequences for hair-
pin siRNAs, and screening by Blast search. Specific sequences
of each siRNA were are listed in Table 1.
Several KEpH1-shRNA plasmids were cotransfected with
KEpEGFP plasmids into cultured HEK293 cells to evaluate
their potency in suppressing the expression of KE-EGFP. Two
KE-specific shRNAs, which significantly reduced the expres-
sion of KE genes in HEK293 cells, were identified. As indi-
cated by the EGFP signals, KE fusion proteins in control cells
(Figure 2A) were reduced to approximately 50% by KE-
1528pH1-shRNA plasmids (Figure 2B), which generated
shRNAs targeting the coding sequence including 1,528-1,548
bp. The percentage of fluorescence-positive cells was approxi-
mately 80% and 60% for Figure 2A,B, respectively. In our
pilot experiments for quality controls, the viability was con-
sistently around 90% after each transfection (data not shown).
As shown in these photographs, not all cells were transfected
with equal amounts of plasmids or generated similar amounts
of fusion proteins. Therefore, the reduction of fluorescence
could only be deemed as supporting evidence since the detec-
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Figure 4. Myocilin-specifc hairpin siRNAs targeting various mutation regions.  Myocilin-specific shRNAs were generated from shMYOCpH1
plasmids that targeted amino acids including R76 (A), E352 (B), K423 (C), and N480 (D) of myocilin protein. Mutations of these residues
have been associated with POAG and JOAG. R76 is located in the myosin-like domain of myocilin whereas the other three amino acids are
located in the olfactomedin-like domain of myocilin. sp: signal peptide; myosin: myosin-like domain; olfactomedin: olfactomedin-like do-
main.
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tion of fluorescence could be affected by various empirical
conditions such as detection threshold and exposure time. The
most conclusive evidence for the efficacy of shRNAs should
be the final protein reduction in a standardized pool of cells.
Consistent with the results observed in tissue culture (Fig-
ure 2A,B), a representative western blot with a custom-made
anti-KE antibody confirmed that when compared with the
control shRNA (Figure 2C, lane 1), the expression of KE fu-
sion protein was reduced to approximately 50% by this shRNA
(Figure 2C, lane 2, arrowhead). Northern hybridization fur-
ther confirmed the reduction of KE-EGFP mRNA by KE-
1528pH1-shRNAs in HEK293 cells (Figure 2D, right lane)
when compared with the control shRNA (Figure 2D, left lane).
Another KE-3’UTR-5pH1-shRNA plasmid (generating
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Figure 5. Suppression of MYOC-EGFP by short hairpin RNAs specific to various coding regions of MYOC in cultured HEK293 cells.  A:
Representative photographs of HEK293 cells from fluorescence microscopy after cotransfection of MYOCpEGFP with various shMYOCs
are shown. The fluorescence photographs were taken with the same exposure times at 48 h after cotransfection. C: Cotransfection of
MYOCpEGFP with a control plasmid; 1: Cotransfection of MYOCpEGFP with shMYOC-A; 2: Cotransfection of MYOCpEGFP with shMYOC-
B; 3: Cotransfection of MYOCpEGFP with shMYOC-C; and 4: Cotransfection of MYOCpEGFP with shMYOC-D. Significant reduction of
MYOC-EGFP was noted in HEK293 cells cotransfected with MYOCpEGFP and shMYOC-A, -B, -C, and -D, respectively (A 1-4). B:
Western blot of protein lysates from cultured HEK293 cells after cotransfection of MYOCpEGFP with various shMYOCs as in A is shown.
Equal amounts of protein lysates from HEK 293 cells (20 µg/lane) were loaded for each lane as indicated by similar intensities of β-actin in
each lane. The MYOC-EGFP fusion protein and β-actin were detected with anti-EGFP and anti β-actin antibodies, respectively. Consistent
with the findings of fluorescence microscopy in A, significant reduction of MYOC-EGFP was noted in HEK293 cells cotransfected with
MYOCpEGFP and shMYOC-A, -B, -C, and -D, respectively (lanes 1-4). These protein bands were then digitized to quantify the suppression
efficiency of each shRNA (see the Results section for average suppression efficiency of each shMYOC).
2089
siRNAs targeting the 3'-UTR region) suppressed greater than
80% of the KE-EGFP in HEK293 cells (Figure 3A,B). West-
ern blot of protein lysates from HEK293 cells further con-
firmed a significant suppression of KE fusion proteins (greater
than 80% as shown in Figure 3C, lane 2, arrowhead) by this
shRNA. These results indicated that these two shRNAs could
effectively suppress the expression of KE gene. Similar sup-
pression of KE-EGFP mRNA was also confirmed by North-
ern hybridization (data not shown). In summary, by transfect-
ing HEK293 cells at 70%-90% confluency, we identified two
shRNAs that could effectively suppress the expression of KE
fusion proteins by approximately 50% and 80%, respectively.
Identification of myocilin-specific short hairpin RNAs:
From the published coding sequence of human MYOC, 102
candidate siRNAs were initially identified. Candidate siRNAs
with sequences covering amino acids R76, E352, K423, or
N480 were chosen to test their suppression efficiencies as
mutations of these residues have been reported to be associ-
ated with POAG (Table 1 and Figure 4). The Blast search in-
dicated that these siRNAs were specific for human MYOC.
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Figure 6. Suppression of wild-type (MYOC-WT) and mutant Q368X
(MYOC-Q368X) myocilin proteins by shMYOC-A (siMYOC-A) in
TM5 cells.  A: Western blot of protein lysates from cultured HEK293
cells after cotransfections of MYOCpEGFP or MYOCQ368XpEGFP
with control pH1-RNA or shMYOC-A plasmids is shown. The
myocilin fusion protein and β-actin were detected with anti-EGFP
and anti β-actin antibodies, respectively. After cotransfection of
MYOCpEGFP with control pH1-RNA, abundant wild-type MYOC-
EGFP was noted in HEK 293 cell lysates. Moderate suppression of
wild-type MYOC-EGFP by shMYOC-A was noted after
cotransfection of MYOCpEGFP with shMYOC-A (MYOC-WT).
Similarly, abundant mutant Q368X-EGFP was noted in HEK 293
cell lysates after cotransfection of MYOCQ368XpEGFP with con-
trol pH1-RNA. Moderate reduction of mutant Q368X-EGFP was
noted after cotransfection of MYOCQ368XpEGFP with shMYOC-
A (MYOC-Q368X). B: Suppression efficiency of wild-type and
mutant myocilins by shMYOC-A is shown in a graph. The protein
bands from A were digitized to quantify the suppression efficiency
of shMYOC-A on wild-type MYOC-EGFP and mutant Q368X-EGFP
using UN-SCAN-IT software. The pixel intensities from the myocilin
fusion proteins were normalized to the pixel intensities from the β-
actin bands. The ratio of intensities between the control shRNA and
shMYOC-A was used to determine the suppression efficiency. Com-
pared with their respective control of wild-type (MYOC-WT) and
mutant Q368X (MYOC-Q368X) myocilins, shMYOC-A reduced the
expression of MYOC-WT and MYOC-Q368X to 58.9%±10.6% (the
asterisk indicates a p<0.02) and 60.8%±6.4% (the double asterisk
indicates a p<0.03), respectively (n=3, bars=SD).
Figure 7. BiP activation as a stress response to myocilins in TM5
cells by luciferase reporter assays.  BiPpGL3 vector was cotransfected
in TM5 cells with either MYOCpEGFP (MYOC-WT) or
MYOCQ368XpEGFP (MYOC-Q368X) along with control pH1-
RNA or shMYOC-A. Dual luciferase assays were performed at 48 h
after transfections. The results were from three independent trans-
fection experiments and each experiment was tested in triplicates
(n=9, bars=SD). The activity of BiP in TM5 cells after the
cotransfection of MYOCpEGFP (MYOC-WT) and control pH1-RNA
was used as a baseline control (100%, as seen in the second bar).
Compared with the baseline, cotransfection of pEGFP (without
MYOC) and the control, pH1-RNA, showed less activation of BiP in
TM5 cells (as shown in the first bar), indicating that the presence of
MYOC-WT could induce moderate stress response in TM5 cells.
Significant activation of BiP was noted in TM5 cells after
cotransfection of MYOCQ368XpEGFP (MYOC-Q368X) and con-
trol pH1-RNA plasmids, indicating that mutant MYOC-Q368X in-
duced a more pronounced stress response than MYOC-WT (The as-
terisk indicates that p<0.001, as seen in the third bar). Cotransfection
of shMYOC-A significantly reduced the activation of BiP induced
by mutant MYOC-Q368X (The double asterisk indicates that
p<0.001, as seen in the fourth bar), indicating shMYOC-A could re-
duce the stress response induced by the mutant myocilin to a baseline
level similar to that induced by wild-type myocilin.
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These candidate siRNAs had neither a sequence similarity to
EGFP nor the capability of suppressing EGFP expression when
tested in cultured HEK293 cells (data not shown). The tar-
geted myocilin domains of these shRNAs were shown in Fig-
ure 4. One shRNA was targeted at the myosin-like domain
(R76, shMYOC-A), and the other three were targeted at the
olfactomedin region (E352, shMYOC-B; K423, shMYOC-C;
and N480, shMYOC-D).
Plasmids generating MYOC-specific shRNAs were
cotransfected with MYOCpEGFP to evaluate their efficiency
of suppressing myocilin expression in cultured HEK293 cells.
As shown in the representative photographs of Figure 5A 1-4,
evident reduction of MYOC-EGFP fluorescence was noted in
HEK293 cells cotransfected by MYOCpEGFP with shMYOC-
A, -B, -C, or-D, respectively, when compared with control
shRNA (Figure 5A,C). These results suggested that success-
ful suppression of fusion proteins was achieved by these
MYOC-specific shRNAs.
The suppression of MYOC-EGFP proteins by these
MYOC-specific shRNAs was further confirmed by western
blots of HEK293 cell lysates after each shRNA was
cotransfected with MYOCpEGFP. As shown in one of the rep-
resentative blots (Figure 5B), shRNAs targeting regions sur-
rounding amino acids R76, E352, K423, and N480, respec-
tively, were effective in suppressing the expression of MYOC-
EGFP fusion proteins (lanes 1-4) when compared with a con-
trol shRNA (lane C). The staining intensity of β-actin indi-
cated comparable protein loadings in each sample. The reduc-
tion of MYOC-EGFP intensity was further quantified with
UN-SCAN-IT software on digitized protein bands of the west-
ern blots. When compared with the control siRNA (Figure 5B,
lane C), the expression of MYOC-EGFP was reduced to
13.3%±10.9%, 10.2%±15.3%, 10.5%±14.2%, and
11.3%±9.9% (mean±SD, n=5) by shMYOC-A, -B, -C, and -
D, respectively. When compared with the control shRNA, all
of these four MYOC-specific shRNAs showed statistically sig-
nificant suppression of myocilin in HEK293 cells (Student’s
t-test, p<0.05). Reduction of MYOC-EGFP mRNAs by these
shRNAs was also noted, but we did not specifically quantify
the percentage of reduction (data not shown). As shown by
analyses with western blots, these MYOC-specific shRNAs
on average achieved between 80%-90% reduction of myocilin
fusion protein in HEK293 cells when transfected at 70%-90%
cell confluency.
Suppression of mutant myocilin by short hairpin RNAs in
cultured TM5 cells:  In addition to suppressing wild type
myocilin, the suppression of mutant myocilins in TM5 cells, a
transformed cell line of trabecular meshwork, by those
myocilin-specific shRNAs was further evaluated. Such experi-
ments were conducted in TM5 cells rather than the routine
HEK293 cells to simulate glaucoma in vitro. As shown in Fig-
ure 6A, when compared with the control pH1-RNA plasmid,
shMYOC-A effectively reduced the expression of both
MYOC-EGFP (wild type) and the Q368X-EGFP mutant in
TM5 cells. Using UN-SCAN-IT software to digitize the pro-
tein bands of western blots, the expression of MYOC-EGFP
and Q368X-EGFP mutant was reduced by shMYOC-A to
58.9%±10.6% and 60.8%±6.4% of the control level, respec-
tively (Figure 6B). Under these experimental conditions,
shMYOC-A on average suppressed the expression of both wild
type and mutant myocilins by 40% in TM5 cells when trans-
fected at 50% confluency.
Activation of BiP by BiP promoter-driven luciferase as-
say: To further study the capability of MYOC-specific shRNAs
in reducing the cytotoxic effects induced by mutant myocilins,
the activation of BiP, one of the stress-response elements in
endoplasmic reticulum (ER) was investigated in TM5 cells.
Using a BiP promoter-driven luciferase assay, cotransfection
of TM5 cells with MYCOpEGFP plasmids generating wild-
type myocilin (MYOC-WT) and the control shRNA plasmids
along with BiPpGL3 (Figure 7, bar 2) showed a mild increase
of BiP activation when compared with the pEGFP (contain-
ing no myocilin as a baseline control, Figure 7, bar 1). On the
other hand, cotransfection of mutant Q368XpEGFP generat-
ing truncated Q368X mutant myocilin (MYOC-Q368X) with
control shRNA plasmids and BiPpGL3 (Figure 7, bar 3) re-
sulted in statistically significant activation of BiP in TM5 cells
when compared to transfection with MYCO-WT (with an av-
erage increase of 214% BiP activation) or EGFP (with an av-
erage increase of 300% BiP activation). Most importantly,
cotransfection of shMYOC-A with MYOC-Q368X (Figure 7,
bar 4) significantly reduced the activation of BiP to 50% when
compared to cotransfection of MYOC-Q368X with the con-
trol sh-RNA plasmids (Figure 7, bar 3). Furthermore, our re-
sults showed that shMYOC-A could effectively mitigate the
stress response of TM5 cells induced by mutant MYOC-
Q368X (as indicated by BiP activation) to a level comparable
to that induced by wild-type myocilin (MYOC-WT; Figure 7,
cf. bars 2 and 4).
DISCUSSION
 The pathogenesis for genetic diseases could be due to one of
two mechanisms: (1) gain-of-function (for example, mutant
proteins generate cytotoxic or pathogenic effects) or (2) loss-
of-function or haloinsufficiency (such as the failure of pro-
ducing sufficient amount of proteins to achieve or maintain
proper cellular functions). RNA interference (RNAi) is a use-
ful tool to silence those untoward gene mutations, especially
the ones associated with abnormal protein production known
as gain-of-function. Accumulation of abnormal KE and
myocilin proteins as a result of gene mutations has been linked
to autosomal dominant corneal stromal dystrophies and cer-
tain types of inherited open-angle glaucoma, respectively.
There is strong evidence suggesting that KE-related corneal
dystrophies and myocilin-related OAGs are due to the gain-
of-function mechanism rather than the loss-of-function mecha-
nism. For KE-related corneal dystrophies, it is self-evident
that accumulation of mutant proteins leads to corneal opaci-
ties and poor epithelial adhesion to the corneal stroma. The
severity of corneal dystrophies correlates well with the extent
of mutant KE aggregations.
There is evidence indicating the presence of misfolded
proteins in glaucoma patients such as overexpression of αB-
crystallin along with myocilin [34] and colocalization of pro-
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tein disulfide isomerase (PDI) with aggregated mutant
myocilin in the endoplasmic reticulum (ER) [16]. When
cDNAs, encoding mutant myocilin, were transfected into cul-
tured TM cells, the expressed mutant myocilins failed to be
secreted extracellularly and formed aggregates of misfolded
proteins inside the TM cells. Mutant myocilins also prevented
the secretion of wild-type protein when cDNAs of both wild-
type and mutant myocilins were cotransfected into cultured
TM cells [14,16]. Since myocilin forms dimers or even oligo-
mers in vivo [35], it is likely that misfolded mutant myocilins
bind and “trap” wild-type proteins inside the cells. Further-
more, it has been demonstrated that the expression of mutant
myocilin in cultured TM cells led to cellular deformity, de-
creased cell proliferation, increased ER stress, and significant
cell death of TM cells [16,28]. Taken together, these data sug-
gest that glaucoma associated with abnormal secretion of
mutant and/or wild-type myocilins in humans are mediated
through a gain-of-function mechanism with untoward cyto-
toxicity and cell death of TM induced by mutant myocilins.
To treat these conditions associated with mutant proteins,
it is logical to suppress the expression of mutant genes to ame-
liorate the accumulation of untoward disease-causing proteins.
In this study, the feasibility of using RNAi to suppress the
expression of KE and MYOC in vitro was explored. Our re-
sults demonstrated that KE-specific and MYOC-specific
shRNAs could effectively suppress the expression of recom-
binant KE and myocilin proteins, respectively, in HEK293 cells
and TM5 cells.
Since our working hypotheses was that myocilin-related
glaucoma is induced by the misfolding of mutant myocilins
and related cytotoxicity of TM, shRNAs that suppress the ac-
cumulation of mutant myocilins may potentially be used to
mitigate the adverse consequences in TM cells. Many myocilin
mutations linked to POAG are missense mutations within the
olfactomedin domain. Among them, the myocilin Q368X non-
sense mutation is one of the most common mutations found in
POAG patients. The experiments of transfecting MYOC-
Q368X into TM5 cells (simulating an empirical glaucoma
model) with subsequent upregulation of BiP reconfirmed the
notion that mutant myocilins can cause an untoward stress
response in TM cells. As shown in Figure 7, suppression of
MYOC-Q368X by myocilin-specific shRNAs indeed reduced
the activation BiP (indicative of reduced ER stress) in TM5
cells. These MYOC-specific shRNAs were capable of suppress-
ing the expression of wild type and mutant myocilins in cul-
tured HEK293 and TM5 cells. More importantly, they could
mitigate the stress response induced by mutant myocilins such
as MYOC-Q368X. Their high suppression efficiency and their
capabilities of reversing the cytotoxicity induced by mutant
myocilins should render them as a potential for future studies
on the functions of myocilin.
It remains unclear whether cell death of TM is linearly
correlated with the accumulation of mutant myocilins. In other
words, what is the relationship between the reduction of mu-
tant proteins and the improved survival of TM cells? In this
study, 100% suppression of myocilin could not be achieved
by any individual shRNA of ours. These four shRNAs sup-
pressed MYOC-EGFP fusion proteins up to 90% in HEK293
cells and around 40% in TM5 cells (Figure 6B, bar 2) with a
linear dose-response of MYOC suppression by MYOC-
shRNAs in the cotransfection experiments (data not shown).
Increases in dosages of MYOC-shRNAs rendered more sup-
pression of MYOC fusion proteins. The dose or molar ratio of
siRNA to target gene will be an important factor to consider
when applying RNAi technology for potential clinical use.
Although the BiP activation by Q368X mutant myocilins was
effectively reduced by shMYOC-A to a baseline level induced
by wild type myocilin (MYOC-WT in Figure 7) in TM5 cells,
the correlation between the suppression of mutant myocilins
and the increased survival of TM5 cells has not yet been es-
tablished.
While being able to devise shRNAs with successful sup-
pression of wild type KE and myocilin in vitro as demon-
strated herein, we intend to further investigate the feasibility
of using mutation-specific siRNAs to selectively suppress the
mutant genes. Since the physiological functions of KE and
myocilin proteins still remain unclear, the nondiscriminating
nature of those shRNAs used in this study certainly raises the
concerns of safety regarding their clinical applications. Their
safety and efficacy profiles should be further evaluated in vivo,
preferably using pertinent animal models. To the best of our
knowledge, multiple attempts to produce transgenic animals
with genetic knock-in or knockout of KE have failed to show
any corneal phenotype consistent with corneal stromal dys-
trophies or other systemic pathology (personal communica-
tions with Dr. Gordon Klintworth, Duke University, Durham,
NC, December, 2006). Similarly, MYOC-knockout mice did
not reveal any discernable phenotype with normal IOP being
noted in MYOC-null animals [36]. Furthermore, patients with
the deletion of MYOC did not develop glaucoma or other ocu-
lar abnormalities [37]. It was estimated in a recent study that
3% of the Asian control subjects carrying an Arg46Stop mu-
tation, which results in a severely truncated form of myocilin,
missing more than 90% of amino acids of the wild-type pro-
tein, were not affected by glaucoma [38]. Among many indi-
viduals carrying this Arg46Stop mutation, only a few were
found to have evidence of glaucoma [38,39]. The fact that
patients with a deleted MYOC gene or with the Arg46Stop
mutation remain asymptomatic and that no phenotype has been
observed in KE-knockout animals further supports the notion
that loss of wild-type myocilin or keratoepithelin as a result
of RNAi should not result in significant ocular pathology. Con-
sequently, these findings may also argue in favor of using the
non-selective suppression of KE-related or myocilin-related
mutations for clinical applications.
Although several reports have indicated that mutation-
specific suppression can be achieved in various genes [40,41],
others have questioned whether such specificity could actu-
ally be achieved or would be necessary due to the RNAi mecha-
nism. It has been suggested that during the course of RNAi,
the target mRNA is converted to long dsRNA and enzymati-
cally digested by Dicer into siRNAs [42]. These newly gener-
ated siRNAs will in turn “amplify” and drive gene silencing
further, resulting in a chain reaction of mRNA degradation. In
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other words, although the initiation of RNAi can be directed
to the mutant mRNA, the mutant-specific siRNA may eventu-
ally suppress wild-type mRNAs in trans via siRNA amplifi-
cation.
While our MYOC-specific shRNAs could effectively sup-
press the expression of myocilin, it remains possible that com-
plete removal of mutant proteins is necessary to abolish the
cytotoxic effect exerted by mutant myocilins. Our MYOC-
shRNAs were originally designed based on their potential
ability to inhibit a target mutation selectively. However, to
our pleasant surprise, these shRNAs showed potent suppres-
sion of both wild-type and mutant myocilins under our ex-
perimental conditions. Since there is no adverse effect observed
in MYOC-knockout animals, these nonselective shRNAs may
potentially be used for myocilin-related glaucoma. As such,
they may be used as an individual agent or as a mixture of
shRNAs to alleviate nonselectively the aggregations of mu-
tant and/or wild type myocilins. We intend to further explore
the synergistic effects of these shRNAs by combining all or
some of them to achieve maximal or complete myocilin sup-
pression. Instead of using mutation-specific shRNAs to selec-
tively suppress both copies of the mutant gene in homozy-
gous cells, such a “shotgun” approach by combining nonse-
lective shRNAs targeting the nonmutated sequence to sup-
press both wild type and mutant myocilins may more effec-
tively reduce myocilin-related cytotoxicity in heterozygous
cells (containing one copy of the wild type gene and one copy
of the mutant gene). Such an approach is advantageous in that
shRNA treatment does not need to be tailored to each glau-
coma-related mutation individually. If needed, a synthetic
myocilin gene that has silent mutations to escape from the
suppression of shRNA could then be introduced into cells to
restore the expression of myocilin. Such a strategy known as
“gene switching” has been proposed as a potential therapy for
gain-of-function genetic diseases [43]. Conversely, those two
KE-specific shRNAs were not designed to specifically target
any point mutation of KE. They most likely suppress the ag-
gregation of both mutant and wild-type KEs thereby offering
the potential advantage for being universal agents to suppress
any given KE mutation. Nonetheless, all these shRNAs will
have to be thoroughly evaluated in animal models or other
relevant in vitro systems before any conclusion regarding their
potential clinical application can be drawn.
As shown in our results, the applicability of RNAi can be
affected by cell type, cell density, and various experimental
conditions. Interestingly, a temperature-dependent gene silenc-
ing was noted among several commercially available synthetic
myocilin-specific siRNAs in a recent report [44]. The myocilin
suppression efficiency by these synthetic siRNAs ranged from
30%-70% at temperatures from 33 °C to 37 °C. Such an effect
is likely related to the thermally-modulated folding status of
mRNA and its propensity of a particular region to be base
paired or single-stranded. The suppression efficiency of those
synthetic siRNAs is lower than what has been observed in our
shRNAs, albeit those synthetic siRNAs and our shRNAs tar-
get different regions of the MYOC gene. Since our in vitro
studies were done with cultured HEK293 cells at 37 °C, the
efficacy of our shRNAs may be affected by the local tissue
temperature in vivo studies especially the anterior segment of
the eye with the surrounding temperature being cooler than
the core temperature of the body. Compared with synthetic
siRNAs, shRNAs are likely to be more thermally stable and
less susceptible to RNA degradation, given its looped hair-pin
configuration. Regardless, we believe that our study is the first
in vitro investigation on exploring the use of shRNAs to in-
hibit the synthesis of myocilin and keratoepithelin.
Protein misfolding and conformational changes are the
main causes of many diseases such as cystic fibrosis and
Alzheimer disease [45]. Therefore, these diseases are known
as “conformational diseases”. In each condition, the mutated
or degraded form of disease-associated proteins together with
other nonprotein components show a tendency to form fibril
or plaque (amyloid-like) structures. Fibril or amyloid forma-
tion of the mutated proteins may be the underlying cause of
these conformational diseases. KE-related corneal dystrophies
have characteristic stromal deposits of rod-shaped amyloid or
curly, non-amyloid fiber aggregates. We therefore surmise that
those abnormal stromal deposits are caused by a misfolding
or conformational change of mutant KEs and may contribute
to the observed clinical morbidities. Interestingly, even though
mutations are present systemically in affected individuals with
KE-related corneal dystrophies, the cornea seems to be the
only tissue known to be affected. Current therapies are lim-
ited to supportive treatment for corneal erosions at the early
stages and invasive superficial keratectomy or penetrating
keratoplasty for corneal opacities at the advanced stages. Such
a unique tissue-specific expression of gene mutation makes
KE-related corneal dystrophies ideal candidates for a tissue-
specific gene manipulation instead of difficult systemic gene
therapy with stem cells. Although we are confident that RNAi
can suppress the expression of mutant KEs or myocilins, al-
ternative strategies to suppress the aggregation of disease-caus-
ing proteins do exist. Recently, we have reported on the suc-
cessful use of several short synthetic KE peptides with N-
methylation of selective amino acids (known as meptides) to
reduce the amyloid aggregates of recombinant KE in vitro [46].
Despite the ongoing enthusiasm about the potential ocu-
lar applications of RNAi, several recent studies using highly
sensitive microarray analyses have shown that siRNAs can
have off-target effects by silencing unintended genes [47,48].
These unwanted off-target effects can be potentially minimized
by modifying the siRNAs to prevent incorporation of the sense
strand into RNA-induced silencing complex (RISC) or by se-
lecting sequences with minimal complementarities to other
known genes in the database [49]. Choosing siRNAs that are
effective at low concentrations may also help abrogate or side-
step some of these problems. At present, the lack of animal
models for KE-related corneal dystrophies or myocilin-related
glaucoma precludes us from investigating any unintended off-
target effects of our shRNAs. In summary, this report demon-
strated the feasibility of using shRNAs as effective “molecu-
lar silencers” to suppress the expression of KE and myocilin
in vitro.
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